The gastrointestinal therapeutics market was valued at $39.5 billion in 2022 and is estimated to reach $64.5 billion by 2032, exhibiting a CAGR of 5.0% from 2023 to 2032. Gastrointestinal therapeutics refers to the branch of medical science and healthcare focused on the diagnosis, treatment, and management of disorders and diseases affecting the gastrointestinal (GI) tract. The GI tract is a complex system responsible for the digestion and absorption of food, as well as the elimination of waste. It includes organs such as the mouth, esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. Medications used in GI therapeutics include antacids, proton pump inhibitors, antiemetics, laxatives, antispasmodics, anti-inflammatory drugs, immunosuppressants, and others.
Ongoing research in fields such as gastroenterology, immunology, and microbiology contribute to a deeper understanding of the underlying causes and mechanisms of gastrointestinal disorders. This knowledge leads to the development of targeted therapies and more personalized treatment approaches. The gastrointestinal therapeutics market has experienced significant growth owing to the rise in prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). For instance, according to the National Center for Biotechnology and Information (NCBI) in 2022, gastroesophageal reflux disease (GERD) is one of the most commonly diagnosed digestive disorders in the U.S. with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs. As these disorders affect millions of people worldwide, there is a surge in demand for effective therapeutic options, which is expected to drive market growth.
In addition, the development of biologic therapies has revolutionized the treatment landscape for gastrointestinal disorders, which further supports the market growth. Biologics, such as monoclonal antibodies and cytokine inhibitors, provide targeted interventions that modify the inflammatory processes associated with disorders such as Crohn's disease and ulcerative colitis. Furthermore, ongoing research and development activities in the field of gastrointestinal therapeutics contribute toward the market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available gastrointestinal therapeutics. For instance, Inspirna, Inc. is conducting a phase 1 study of RGX-202-01 (Ompenaclid) as combination therapy in 2nd Line RAS mutant advanced colorectal cancer. Thus, a rise in ongoing research and development activities in the field of gastrointestinal therapeutics is expected to drive the market growth.
The gastrointestinal therapeutics market is segmented into drug class, application, distribution channel, and region. By drug class, the market is segregated into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. By application, the market is classified into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn’s disease and ulcerative colitis. The peptic ulcer disease segment further categorized into the gastric ulcer and duodenal ulcer. By distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Others).
Major key players that operate in the gastrointestinal therapeutics market are AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company. Key players have adopted product launch, product approval, and clinical trial as key developmental strategies to improve the product portfolio of the gastrointestinal therapeutics market.
Ongoing research in fields such as gastroenterology, immunology, and microbiology contribute to a deeper understanding of the underlying causes and mechanisms of gastrointestinal disorders. This knowledge leads to the development of targeted therapies and more personalized treatment approaches. The gastrointestinal therapeutics market has experienced significant growth owing to the rise in prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS). For instance, according to the National Center for Biotechnology and Information (NCBI) in 2022, gastroesophageal reflux disease (GERD) is one of the most commonly diagnosed digestive disorders in the U.S. with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs. As these disorders affect millions of people worldwide, there is a surge in demand for effective therapeutic options, which is expected to drive market growth.
In addition, the development of biologic therapies has revolutionized the treatment landscape for gastrointestinal disorders, which further supports the market growth. Biologics, such as monoclonal antibodies and cytokine inhibitors, provide targeted interventions that modify the inflammatory processes associated with disorders such as Crohn's disease and ulcerative colitis. Furthermore, ongoing research and development activities in the field of gastrointestinal therapeutics contribute toward the market growth. Pharmaceutical companies, academic institutions, and research organizations invest in discovering and developing innovative therapies, improving treatment efficacy, and expanding the range of available gastrointestinal therapeutics. For instance, Inspirna, Inc. is conducting a phase 1 study of RGX-202-01 (Ompenaclid) as combination therapy in 2nd Line RAS mutant advanced colorectal cancer. Thus, a rise in ongoing research and development activities in the field of gastrointestinal therapeutics is expected to drive the market growth.
The gastrointestinal therapeutics market is segmented into drug class, application, distribution channel, and region. By drug class, the market is segregated into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. By application, the market is classified into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn’s disease and ulcerative colitis. The peptic ulcer disease segment further categorized into the gastric ulcer and duodenal ulcer. By distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Others).
Major key players that operate in the gastrointestinal therapeutics market are AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company. Key players have adopted product launch, product approval, and clinical trial as key developmental strategies to improve the product portfolio of the gastrointestinal therapeutics market.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gastrointestinal therapeutics market analysis from 2022 to 2032 to identify the prevailing gastrointestinal therapeutics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the gastrointestinal therapeutics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global gastrointestinal therapeutics market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
- Quarterly update (only available with the purchase of an enterprise license)
- 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
- Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
- 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
- Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
- Free report update, if the report is 6-12 months old or older.
- 24-hour priority response
- Free industry updates and white papers.
Key Market Segments
By Drug Class
- Biologics
- Proton Pump Inhibitors
- Aminosalicylates
- Antacids
- Laxatives
- H2 Antagonists
- Others
By Application
- Inflammatory Bowel Disease
- Type
- Crohn’s Disease
- Ulcerative Colitis
- Gastroesophageal Reflux Disease
- Peptic Ulcer Disease
- Type
- Gastric Ulcer
- Duodenal Ulcer
- Irritable Bowel Syndrome
- Others
By Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Bayer AG
- Bausch Health Companies Inc.
- Cosmo Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Limited
- AbbVie Inc.
- Organon Group of Companies
- Pfizer Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Company
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: GASTROINTESTINAL THERAPEUTICS MARKET, BY DRUG CLASS
CHAPTER 5: GASTROINTESTINAL THERAPEUTICS MARKET, BY APPLICATION
CHAPTER 6: GASTROINTESTINAL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: GASTROINTESTINAL THERAPEUTICS MARKET, BY REGION
CHAPTER 8: COMPETITIVE LANDSCAPE
CHAPTER 9: COMPANY PROFILES
List of Tables
List of Figures
Executive Summary
The Gastrointestinal Therapeutics Market is likely to experience a significant growth rate of 5.0% from 2023-2032 owing to increase in demand for gastrointestinal drugs from pharmaceutical sector. According to this report, the gastrointestinal therapeutics market was valued at $39.5 billion in 2022, and is estimated to reach $64.5 billion by 2032, growing at a CAGR of 5% from 2023 to 2032. Gastrointestinal therapeutics refers to the branch of medicine and healthcare focused on the diagnosis, treatment, and management of disorders and conditions affecting the gastrointestinal (GI) tract. Gastrointestinal therapeutics involves a range of medical approaches, including medications, surgical interventions, lifestyle modifications, and dietary recommendations, aimed at addressing various GI disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), peptic ulcers, diarrhea, and more. The field aims to alleviate symptoms, promote healing, manage complications, and improve overall well-being for individuals experiencing gastrointestinal health issues.
Key factors driving the growth of the gastrointestinal therapeutics market include the rise in prevalence of rise in prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and others. For instance, in 2022, the American Cancer Society estimates a total 106,180 new cases of colon cancer and 46,050 cases of rectal cancer in U. S. This growing incidence of gastrointestinal diseases is driving the demand for gastrointestinal therapeutics as a treatment option. In addition, the rise in awareness about gastrointestinal diseases, advancements in diagnostic techniques resulted in early detection and diagnosis of gastrointestinal diseases. This led to an increase in the demand for gastrointestinal therapeutics.
In addition, growing awareness about early diagnosis of gastrointestinal diseases and their management in developing countries led to the increase in demand for the gastrointestinal therapeutics drugs that propels the market growth. Furthermore, ongoing research and development efforts aim to improve the efficacy, safety, and specificity of gastrointestinal therapeutics medications are anticipated to propel the market growth.
Moreover, the rise in geriatric population suffering from gastrointestinal diseases have a significant impact on driving the growth of the gastrointestinal therapeutics market. The geriatric population is more susceptible to a variety of GI disorders, including gastroesophageal reflux disease (GERD), peptic ulcers, constipation, diverticular disease, and colorectal cancer. The higher disease burden among older adults leads to an increased demand for effective treatment options, thereby driving market growth.
The market also offers growth opportunities to the key players in the market. The rise in R&D activities within the field of gastrointestinal therapeutics offers significant opportunities for market growth. As scientific understanding of gastrointestinal diseases deepens and innovative treatment approaches emerge, these R&D efforts pave the way for new therapeutic options, improved patient outcomes, and expanded market potential. For instance, in June 2023 Erasca, Inc. conducted a clinical trial to study ERAS-007 in patients with advanced gastrointestinal malignancies. In addition, the rise in funding activities, demand for better healthcare facilities and surge in need for gastrointestinal therapeutics thereby provide the lucrative opportunity to the market growth.
The gastrointestinal therapeutics market is segmented into m drug class, application, distribution channel and region. On the basis of drug class, the market is categorized into biologics, proton pump inhibitors, aminosalicylates, antacids, laxatives, H2 antagonists, and others. By application, the market is classified into inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, irritable bowel syndrome, and others. The inflammatory bowel disease segment is further categorized into Crohn’s disease and ulcerative colitis. The peptic ulcer disease segment further categorized into the gastric ulcer and duodenal ulcer. On the basis of distribution channel, it is segregated into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, it is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific ((Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The key players profiled in the study include AstraZeneca plc, AbbVie Inc., Pfizer Inc., AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Organon Group of Companies, Bausch Health Companies Inc., Cosmo Pharmaceuticals, Teva Pharmaceutical Industries Limited, and Bristol-Myers Squibb Company. The players in the market have been actively engaged in the adoption of various strategies such as product launch, product approval, and clinical trials to remain competitive and gain an advantage over the competitors in the market. For instance, in September 2021, Takeda Pharmaceutical Company Limited announced that it has received approval from the Japan Ministry of Health, Labour and Welfare to manufacture and market Alofisel (darvadstrocel) for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's disease (CD).
Key Market Insights
By drug class, the biologics segment was the largest revenue contributor to the market and is estimated to reach $25.52 billion by 2032, with a highest CAGR of 6.9%.By application, the inflammatory bowel disease segment dominated the global market with a highest CAGR of 5.5% during the forecast period.
Based on distribution channel, the drug store and retail pharmacies segment was the largest revenue contributor to the market. However, the online providers segment is anticipated to grow at the highest CAGR of 5.6% during the forecast period.
Based on region, North America garnered the largest revenue share in 2022, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
Companies Mentioned
- Bayer AG
- Bausch Health Companies Inc.
- Cosmo Pharmaceuticals
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Limited
- AbbVie Inc.
- Organon Group of Companies
- Pfizer Inc.
- AstraZeneca plc
- Bristol-Myers Squibb Company
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
